Oramed Pharmaceuticals Inc. (ORMP) is a Biotechnology company in the Healthcare sector, currently trading at $3.82. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ORMP = $37.98 (+894.2% from the current price, the stock appears undervalued).
Valuation: ORMP trades at a trailing Price-to-Earnings (P/E) of 1.9 (S&P 500 average ~25).
Financials: revenue is $2M, -75.2%/yr average growth. Net income is $75M, growing at +54.4%/yr. Net profit margin is 3766.2% (strong). Gross margin is 0.7% (-99.3 pp trend).
Balance sheet: total debt is $825,000 against $200M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.98 (strong liquidity). Debt-to-assets is 0.8%. Total assets: $98M.
Analyst outlook: 6 / 8 analysts rate ORMP as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 50/100 (Partial), Health 100/100 (Pass), Moat 0/100 (Fail), Future 75/100 (Pass), Income 100/100 (Pass).
